hackint0sh/New-Dataset huggingface dataset:
In this 3-arm RCT, we will recruit adolescents aged 14-18 using an online crowdsourcing platform, to test the efficacy of a) standard BVI that addresses mental health treatment but does not address concerns about peer inclusion/exclusion, b) novel BVI focused on mental health treatment and peer inclusion, and c) control condition that provides information without social contact. conditions: Depression conditions: Adolescent - Emotional Problem conditions: Stigma, Social conditions: Help-Seeking Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 650 type: ESTIMATED name: brief video measure: Depression Stigma Scale (modified) measure: Ultra-brief Self-stigma of Help-Seeking measure: Adolescent Stigma Scale (modified) sex: ALL minimumAge: 14 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: New York State Psychiatric Institute city: New York state: New York zip: 10032 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06360094 id: 1490-0004 id: 2023-510249-79-00 type: REGISTRY domain: CTIS id: U1111-1301-1311 type: REGISTRY domain: WHO Registry (ICTRP) briefTitle: A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis overallStatus: NOT_YET_RECRUITING date: 2024-07-27 date: 2025-07-21 date: 2025-08-06 date: 2024-04-11 date: 2024-04-11 name: Boehringer Ingelheim class: INDUSTRY briefSummary: Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.
Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF.
During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects. conditions: Idiopathic Pulmonary Fibrosis conditions: Progressive Pulmonary Fibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 230 type: ESTIMATED name: BI 1839100 name: Placebo measure: IPF cohort - Phase IIa: Change from baseline in 24-h cough frequency (Cough count (CC)/h) measure: IPF cohort - Phase IIb: Change from baseline in 24-h cough frequency (CC/h) measure: IPF cohort - Phase IIa: Absolute change from baseline in Cough Severity Numerical rating scale (NRS) score measure: IPF cohort - Phase IIa: Absolute change from baseline in Cough Severity Visual analogue scale (VAS) score (mm) measure: IPF cohort - Phase IIb: Cough responder status, defined as a ≥30% reduction in 24-h cough frequency (CC/h) measure: IPF cohort - Phase IIb: Absolute change from baseline in Forced vital capacity (FVC) (mL) measure: IPF cohort - Phase IIb: Absolute change from baseline in Cough Severity NRS score measure: IPF cohort - Phase IIb: Absolute change from baseline in Cough Severity VAS score (mm) measure: IPF cohort - Phase IIb: Absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) symptom cough domain score measure: IPF cohort - Phase IIb: Absolute change from baseline in Leicester Cough Questionnaire (LCQ) physical domain score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360081 id: 1479-0019 id: 2023-510495-31-00 type: OTHER domain: CTIS id: U1111-1303-4345 type: OTHER domain: WHO briefTitle: A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2024-06-24 date: 2024-06-24 date: 2024-04-11 date: 2024-04-11 name: Boehringer Ingelheim class: INDUSTRY briefSummary: The main objective of this trial is to establish the bioequivalence of zongertinib tablet from manufacturer 1 (Test, T) compared with zongertinib tablet from manufacturer 2 (reference, R) following oral administration. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: Zongertinib measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72h (AUC0-72h) measure: Maximum measured concentration of the analyte in plasma (Cmax) measure: Time from dosing to maximum measured concentration of the analyte in plasma (tmax) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06360068 id: SLE-SASP POC id: 82371767 type: OTHER_GRANT domain: National Natural Science Foundation of China briefTitle: A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2025-05-01 date: 2025-05-01 date: 2024-04-11 date: 2024-04-11 name: Qiong Fu class: OTHER briefSummary: The goal of this clinical trial is to learn if sulfasalazine is safe and feasible in the treatment of active lupus erythematosus (SLE). The main questions it aims to answer are:
Visit the clinic once every 4 weeks for checkups and tests. conditions: Systemic Lupus Erythematosus studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Sulfasalazine Tablets measure: the change of disease activity (SLEDAI score) measure: the number of patients who can reach SRI-4 measure: the change of prednisone dosage measure: the change of interferon stimulating genes (ISG) expression sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360055 id: M2024130 briefTitle: Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults overallStatus: RECRUITING date: 2024-04-01 date: 2024-11-30 date: 2024-12-31 date: 2024-04-11 date: 2024-04-11 name: Peking University Third Hospital class: OTHER briefSummary: The aim of this study is to investigate the effects of oral D-mannose tablets for 2 consecutive weeks on the pharmacokinetics of dabigatrun etexilate, a P-glycoprotein probe substrate drug, in healthy adults conditions: Health studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: BASIC_SCIENCE masking: NONE count: 12 type: ESTIMATED name: Dabigatran Etexilate name: D-mannose measure: Plasma concentration of dabigatran measure: Serum concentrations of glycoomics such as D-mannose sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Peking University Third Hospital status: RECRUITING city: Beijing state: Beijing zip: 100191 country: China name: Cheng Cui role: CONTACT email: cuicheng1226@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06360042 id: MA-HCC-II-021 briefTitle: Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC overallStatus: RECRUITING date: 2024-01-01 date: 2027-03-31 date: 2028-03-31 date: 2024-04-11 date: 2024-04-22 name: Peking University Cancer Hospital & Institute class: OTHER briefSummary: This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC. conditions: Unresectable Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 111 type: ESTIMATED name: Adebrelimab plus Apatinib name: Adebrelimab plus Bevacizumab name: Camrelizumab plus Apatinib measure: 12-month overall survival rate measure: ORR measure: DCR measure: DoR measure: TTR measure: TTP measure: PFS measure: OS measure: safety according to NCI Common Terminology Criteria for Adverse Events, version 5.0. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing state: Beijing country: China name: Jun Zhou role: CONTACT phone: 13366152815 email: Joelbmu@126.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06360029 id: LvL UP briefTitle: The LvL UP Pilot Trial overallStatus: RECRUITING date: 2024-04-15 date: 2024-06 date: 2024-06 date: 2024-04-11 date: 2024-04-17 name: Singapore ETH Centre class: OTHER name: ETH Zurich name: National University of Singapore name: Nanyang Technological University briefSummary: Non-communicable diseases (NCDs), such as cardiovascular disease, diabetes, or cancer, and common mental disorders (CMDs), such as depression or anxiety, represent the primary causes of death and disability worldwide, causing major health and financial burdens. Lifestyle behaviours, including physical activity, diet, stress and emotional regulation, tobacco smoking, alcohol consumption, and sleep are important modifiable risk factors associated with the prevention and management of both NCDs and CMDs.
nctId: NCT06360016 id: Protocol-RAP briefTitle: Protocol of Self-Regulation in Early Learners: The Role of Recreational Programs acronym: Protocol-RAP overallStatus: COMPLETED date: 2023-02-13 date: 2023-05-31 date: 2024-02-01 date: 2024-04-11 date: 2024-04-11 name: Selcuk University class: OTHER name: University of Malaga briefSummary: Protocol of Self Regulation in Early Learners: The Role of Recreational Activity Program (RAP) RAP, which included fun games and lasted 24 sessions, was applied to the students in the study group. Twenty-four sessions include games that help gain rhythm, balance, and patience. The program is planned according to the game theory model, which aims to have fun for children. The program, which aims to develop children's self-regulation skills based on the essential reflections of the model, will include fun games with simple rules. Before the program was implemented, the researchers informed the experimental group about the research and the program, and verbal consent was obtained from the participants. conditions: Self Regulation conditions: Impulsive conditions: Attention Difficulties conditions: Emotion Regulation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: pre and post-test with the control group primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Double (Investigator, Outcomes Assessor) whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 38 type: ACTUAL name: Recreation Activity Program measure: Self-Regulation Assessment sex: ALL minimumAge: 5 Years maximumAge: 6 Years stdAges: CHILD facility: Selcuk University city: Konya zip: 42400 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06360003 id: SAHoWMU-CR2024-01-109 briefTitle: "Right Ventricular Outflow Tract Posterior Septum Pacing" in Predicting Ventricular Outflow Tract Ventricular Tachycardia Origin overallStatus: RECRUITING date: 2023-04-01 date: 2025-04-01 date: 2025-08-01 date: 2024-04-11 date: 2024-04-11 name: Second Affiliated Hospital of Wenzhou Medical University class: OTHER briefSummary: The goal of this clinical trial is to make clear that a new method, right ventricular outflow tract (RVOT) posterior septum pacing, has a greater accuracy in predicting the origin of ventricular outflow tract (VOT) ventricular arrhythmias (VAs) compared to the previous electrocardiographic standards for the identification of the origin of ventricular outflow tract. The secondary aim is to investigate, by using the new method, if it can optimize the procedure of radiofrequency catheter ablation.
The second step will enroll another 100 patients. In this step, patients will be divided into two groups, one being the new protocol group and the other being the convention group. Patients will also be followed up, for 1 month and 3 months at outpatient clinic post procedure. Procedure time, success rate, fluoroscopy exposure time and complications, are compared between RVOT posterior septum pacing group and convention group. conditions: Ventricular Outflow Tract Ventricular Arrhythmias conditions: Radio Frequency Catheter Ablation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Right Ventricular Outflow Tract Posterior Septum Pacing name: systemic mapping and ablation measure: Rate of Immediate Ablation Success measure: Rate of Ablation Complication measure: Accuracy of RVOT posterior septal pacing protocol measure: Incidence of Complications Post-operative measure: Incidence of Complication measure: Rate of Recurrence during Follow up measure: Incidence of Complication measure: Rate of Recurrence during Follow up sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University status: RECRUITING city: Wenzhou state: Zhejiang zip: 325000 country: China name: Cheng Zheng, PhD role: CONTACT phone: 86-0577-85676609 email: zhengcheng_wzmufey@163.com lat: 27.99942 lon: 120.66682 hasResults: False
nctId: NCT06359990 id: RushUMCEmezue briefTitle: BrotherlyACT: A Culturally Congruent and Technology-Enhanced Youth Violence and Substance Use Intervention for Black Boys and Men acronym: BrotherlyACT overallStatus: RECRUITING date: 2024-02-15 date: 2026-02-15 date: 2026-02-15 date: 2024-04-11 date: 2024-04-11 name: Rush University Medical Center class: OTHER briefSummary: This study will adapt and test a culturally tailored, multi-component, and trauma-focused digital intervention to reduce the risk and effects of youth violence and substance use and bridge service access gaps for young Black males (YBM) in pediatric emergency and community-based low-resource settings. conditions: Violence in Adolescence conditions: Substance Use conditions: Avoidance of Healthcare studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: BrotherlyACT name: BrotherlyACT Waitlist Control Group (WCG) measure: The Reactive-Proactive Aggression Questionnaire (RPQ) measure: Multidimensional Peer Victimization Scale (MPVS) measure: The Alcohol Use Disorders Identification Test (AUDIT) measure: Drug Use Disorders Identification Test (DUDIT) measure: Change in Attitude toward Substance Use measure: Emotional Avoidance Strategy Inventory for Adolescents (EASI-A) measure: The Kessler Psychological Distress Scale (K-10) measure: The University of Rhode Island Change Assessment Scale (URICA) measure: Intensity-of-Care Measurements measure: Violent Intentions-Teen Conflict Survey sex: MALE minimumAge: 15 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT facility: Rush University Medical Center status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Chuka N Emezue, PhD, MPH role: CONTACT phone: 312-942-6151 email: chuka_emezue@rush.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06359977 id: YB-202442 briefTitle: The Effect of Quantitative EEG Combined With Ultrasound and Sputum Volume on Predicting Weaning Failure overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-15 date: 2025-05-15 date: 2024-04-11 date: 2024-04-11 name: Qingdao University class: OTHER briefSummary: Neurocritical patients often face the need for removal of endotracheal tubes. However, despite following the extubation criteria for general critical ill patients, neurocritical patients still exhibit a higher rate of weaning failure, significantly higher than that of general critical ill patients. The extubation criteria for general critical patients emphasize the assessment of lung conditions. However, neurological critical patients often have less severe lung damage, but factors such as consciousness level and coughing ability may significantly influence extubation. Quantitative EEG serves as an objective tool to reflect consciousness level status, while bedside ultrasound can assess respiratory muscle function. Additionally, sputum volume may reflect the condition of lung condition. Therefore, we believe that combination of these three indicators can better predict the success of extubation for neurocritical patients. conditions: Weaning Failure studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Quantitative EEG monitoring and beside ultrasound evaluation measure: Quantitative EEG indicators measure: Respiratory muscles thickness in centimeter measure: Respiratory muscles thickening fraction (%) measure: Sputum volume in milliliter sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359964 id: CRE2023.195 briefTitle: Infective Complications in TP Biopsy Without Antibiotic Prophylaxis overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-31 date: 2027-03-31 date: 2024-04-11 date: 2024-04-11 name: Chinese University of Hong Kong class: OTHER briefSummary: This study is a prospective cohort study to delineate the infective outcomes and incidence after transperineal prostate biopsy with no antibiotic prophylaxis, compared to the existing data on outcomes on patients receiving transperineal prostate biopsy with antibiotic prophylaxis. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1900 type: ESTIMATED name: Transperineal Biopsy without antibiotics prophylaxis name: Transperineal Biopsy with antibiotics prophylaxis measure: The difference in UTI hospitalization rate between the two groups after biopsy measure: The difference in urosepsis rates between the two groups after biopsy measure: Post-biopsy UTI rates between the two groups measure: Assessment of bacteriology and antibiotic resistant profile between the two groups sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359951 id: 24-0103 briefTitle: Implementation of Project YES in Ambulatory Adolescent & Young Adult Medicine overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2025-02-01 date: 2026-01-31 date: 2024-04-11 date: 2024-04-11 name: Ann & Robert H Lurie Children's Hospital of Chicago class: OTHER name: American Psychological Association Division 53 Society for Clinical Child & Adolescent Psychology briefSummary: This study tests a suite of single-session intervention (SSI) targeting risk factors for depression and eating disorders among adolescents and young adults. Youth ages 13-25 who screen positive for depression or anxiety as a part of routine care will be offered one of three digital SSIs. Participants will complete questionnaires before the intervention, immediately after the intervention, and 3-months after completing the intervention so that the study team can investigate if Project YES leads to reductions in depression, anxiety and eating disorder symptoms. conditions: Depression conditions: Eating Disorders conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Project YES measure: Short Mood and Feelings Questionnaire (SMFQ; Messer et al., 1995) measure: Patient Health Questionnaire-9 (PHQ-9) measure: Generalized Anxiety Disorder -7 (GAD-7) measure: Dietary Restriction Screener - 2 (DRS 2) measure: Adult State Hope Scale measure: Self-Hate Scale measure: Beck Hopelessness -4 measure: Program Feedback Scale sex: ALL minimumAge: 13 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Ann & Robert H Lurie Children's Hospital of Chicago city: Chicago state: Illinois zip: 60611 country: United States name: Anna M Ros, PhD role: CONTACT phone: 312-227-5433 email: annaros@luriechildrens.org name: Lisa Kuhns, PhD role: CONTACT phone: 312-227-6119 email: lkuhns@luriechildrens.org lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06359938 id: Cer22/01 briefTitle: Respiratory Sinus Arrhythmia Pacing Post-CABG Surgery in Patients With HFrEF acronym: RSA-PACE overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-01 date: 2025-04-01 date: 2024-04-11 date: 2024-04-11 name: Ceryx Medical Ltd class: INDUSTRY name: Cardiff and Vale University Health Board briefSummary: The goal of this clinical trial is to test a new type of pacemaker in heart failure patients following a heart bypass operation. The new pacemaker restores respiratory sinus arrhythmia which is a natural pattern where the heart rate increases when the participants breathe in and slows down when participants breathe out.
Participants will have a range of tests before their operation and during their recovery in hospital while participants have the new type of pacemaker in place, and will be monitored very closely. Participants will also receive a phone call 1 month after their surgery. Researchers will compare the new type of heart pacing against standard treatment to see if it is as safe, and if it is any better for patients. conditions: Heart Failure With Reduced Ejection Fraction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Atrial pacing with respiratory sinus arrhythmia (RSA) variability name: Monotonic right atrial overdrive pacing measure: Number of arrhythmia episodes per patient during pacing sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cardiff & Vale University Health Board city: Cardiff zip: CF14 4XW country: United Kingdom name: Zaheer Yousef role: CONTACT email: CAV_research.development@wales.nhs.uk name: Avraj Virdi role: CONTACT lat: 51.48 lon: -3.18 hasResults: False